SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS

摘要

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty.R ¹ is hydrogen, alkyl, cycloalkyl, 5- to 6-membered heterocycloalkyl, 5- to 10-membered heteroaryl or phenyl; R ² is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R ³ , R ⁴ , R ⁵ , R ⁶ , R ⁷ , R ⁸ are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R ² , R ³ , R ⁴ is H; X ¹ , X ² , X ³ , X ⁴ , X ⁵ , X ⁶ are independently N or C; with the proviso that in each ring maximal one X is N.